CAR-T therapy Follow-Up study shows no new safety surprises
NCT ID NCT04488354
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatment. Researchers also looked at how well the cancer was controlled over time. This was a safety-focused follow-up, not a test of a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
16 people
The number who actually took part.
- Started
-
Jan 2021
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All patients who received at least one CLBR001 cell dose and have either discontinued early or completed the core treatment protocol or any protocol such as a managed access protocol as applicable. * Subject is willing and able to adhere to the study visit schedule and other protocol requirements. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol Exclusion Criteria: * There are no specific exclusion criteria for this study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Burkitt lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
Sarah Cannon Research Institute - Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute - Texas Transplant Institute
San Antonio, Texas, 78229, United States
-
University of California at San Diego
San Diego, California, 92093, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Wake Forest Baptist Health
Winston-Salem, North Carolina, 27157, United States
-
Weill Cornell Medical College - New York Presbyterian Hospital
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Off-the-Shelf Gene-Edited immune cells tested against Hard-to-Treat lymphoma
- Tweaking donor cells may shield older transplant patients from a dangerous complication
- Can a bispecific antibody wipe out residual leukemia cells in High-Risk CLL?
- Proton beams vs. X-Rays: can a pricier radiation spare hearts and prevent second cancers?
- Real-World data may reveal how acalabrutinib performs in chinese blood cancer patients
- Can a drug combo shrink Hard-to-Treat lymphoma tumors?